Health & Biotech Creso Pharma’s acquisition target lands deal with leading US online health marketplace July 25, 2022 Special Report: The deal between Creso’s acquisition target Sierra Sage Herbs could potentially open up a huge opportunity for new… Here are the Top 10 crucial trials coming up for ASX biotechs in 2022 July 25, 2022 What are the top 10 crucial clinical trials that are currently happening with ASX listed biotechs in 2022? Neurotech eyes Phase II/III trial and FDA approval after cannabis breakthrough on paediatric autism July 22, 2022 Special Report: The recent trial results success could pave the way to test other neurological illnesses, as well as an… ASX Health Stocks: Inoviq pockets another US patent, its second in a month July 22, 2022 Diagnostics and exosome specialist Inoviq (ASX:IIQ) has been granted a US patent for its hTERT test platform. Nutritional Growth Solutions just signed a key distribution deal in US July 21, 2022 Special Report: Nutritional Growth Solutions has increased the pace of its US rollout through a deal with the country’s largest… Incannex receives key ethics approval to start Phase 1 clinical trial of multi-use anti-inflammatory drug July 21, 2022 Special Report: Incannex has achieved approval to start a milestone clinical trial into its multi-use, anti-inflammatory drug to treat a… Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs July 21, 2022 US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials… ASX Health Stocks: HeraMED up 17pc and Mesoblast 12pc after strong study results July 19, 2022 HeraMED's device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong study results OncoSil announces success in Spain… Wellnex shares jump ~10% on OneLife Botanicals deal July 18, 2022 Special Report: Investors have reacted favourably to news Wellnex Life has signed a joint venture with OneLife Botanicals positioning the… ASX Health Stocks: Ansell commits to net zero by 2040, but says Scope 3 needs more work July 18, 2022 Ansell announces net zero commitment by 2040 Emyria extends its library of novel MDMA-like compounds to >125 Genetic Technologies partners with Melbourne… Next» « Previous